Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dextrose is a monosaccharide that provides a source of calories and fluid for intravenous administration. It increases blood glucose levels and may cause diuresis via osmotic effects. Sodium chloride provides electrolyte replacement to maintain or restore intravascular volume and extracellular fluid balance.
Aminophylline is a complex of theophylline and ethylenediamine. Theophylline acts as a non-selective phosphodiesterase inhibitor, increasing intracellular cyclic AMP levels, leading to bronchodilation. It also blocks adenosine receptors, stimulates catecholamine release, and enhances diaphragmatic contractility. The ethylenediamine component increases solubility.
FDA: Parenteral source of calories and fluid in patients requiring IV hydration; treatment of hypovolemia; prevention or correction of dehydration and electrolyte imbalances.,Off-label: Adjunctive therapy in the management of hyperkalemia (with insulin); treatment of hypoglycemia.
Treatment of symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases (e.g., emphysema, chronic bronchitis),Adjunctive therapy in acute bronchial asthma and status asthmaticus,Off-label: Treatment of apnea of prematurity
Intravenous infusion; typical adult dose is 100-200 m L/hour of D5 0.9% Na Cl, adjusted based on fluid and electrolyte status, glucose monitoring, and clinical indication.
Loading dose: 5-6 mg/kg IV over 20-30 minutes (if not on theophylline). Maintenance: 0.5-0.7 mg/kg/h IV continuous infusion.
Glucose: ~1.5–2 hours for metabolic clearance in euglycemic individuals; prolonged in renal impairment (adds renal excretion of glucose if threshold exceeded). Dextrose solution constituents (water, sodium, chloride) have no true half-life; water turnover half-life ~3–4 hours in adults.
Terminal elimination half-life: 3-12 hours in adults (mean 5-6 hours); prolonged in hepatic impairment, heart failure, COPD, and neonates (up to 30 hours). Smoking reduces half-life by 30-50%.
Dextrose is metabolized via glycolysis and the citric acid cycle in all tissues; insulin-dependent cellular uptake occurs in most cells. Sodium chloride is not metabolized but is excreted renally.
Theophylline is metabolized primarily in the liver by cytochrome P450 isoenzymes, predominantly CYP1A2, with minor contributions from CYP2E1 and CYP3A4. Metabolism involves N-demethylation and oxidation. In neonates, metabolism is immature; in adults, ~90% is hepatically cleared. Ethylenediamine is minimally metabolized.
Renal elimination of free water and electrolytes. Glucose is metabolized to CO2 and water; excess glucose not metabolized is excreted renally as glucose (glucosuria) when renal threshold exceeded. Sodium and chloride are excreted renally, with >90% of filtered sodium reabsorbed; chloride follows sodium. No biliary or fecal elimination of intact drug.
Renal excretion of unchanged drug (about 10-20%) and metabolites (primarily 1,3-dimethyluric acid, 1-methyluric acid, 3-methylxanthine). Billary/fecal excretion is negligible.
Glucose: negligible binding (<1%). Sodium and chloride: not protein bound.
Theophylline (active moiety): approximately 40% bound to plasma proteins, primarily albumin. Protein binding decreases in neonates, hepatic cirrhosis, and uremia.
Glucose: Vd ~0.15–0.25 L/kg (total body water). Sodium: Vd ~0.25 L/kg (extracellular fluid). Chloride: Vd ~0.25–0.35 L/kg. Water distributes throughout total body water (~0.6 L/kg).
Apparent volume of distribution: approximately 0.4-0.6 L/kg (average 0.45 L/kg). Indicates distribution into total body water; slightly higher in neonates and premature infants.
Intravenous: 100% bioavailable. Not applicable to oral or other routes.
Oral: 96-100% for immediate-release tablets; 50-70% for some sustained-release formulations depending on formulation. Rectal: 70-80% (variable). IV: 100%.
In acute kidney injury or chronic kidney disease, use with caution; monitor for volume overload and hypernatremia. GFR < 30 m L/min: restrict volume to 500-1000 m L/day with careful sodium assessment. GFR 30-50 m L/min: use standard dosing with monitoring. GFR > 50 m L/min: no adjustment required.
No dose adjustment required for GFR >30 m L/min. For GFR 10-30 m L/min: reduce maintenance dose by 50% and monitor serum theophylline levels. For GFR <10 m L/min: reduce maintenance dose by 50% and extend dosing interval or use with caution.
No specific Child-Pugh based dose adjustments; monitor for fluid retention and electrolyte disturbances in decompensated cirrhosis (Child-Pugh B or C). Use with caution in ascites.
Child-Pugh A: reduce dose by 50%. Child-Pugh B: reduce dose by 75%. Child-Pugh C: contraindicated or use with extreme caution, reduce dose by 80% and monitor levels.
Weight-based infusion: neonates 0-28 days: 5-10 m L/hour; infants 1-12 months: 10-20 m L/hour; children 1-12 years: 20-50 m L/hour; adolescents 13-17 years: 50-100 m L/hour. Adjust based on glucose and electrolyte monitoring.
Loading dose: 1 mg/kg IV (if not on theophylline). Maintenance: Continuous infusion: age 6 months-1 year: 0.5 mg/kg/h; age 1-9 years: 0.8 mg/kg/h; age 9-12 years: 0.7 mg/kg/h; age 12-16 years: 0.6 mg/kg/h. Maximum daily dose: 24 mg/kg/day.
Elderly patients: start at lower infusion rates (50-100 m L/hour) and titrate; monitor for fluid overload, hyperglycemia, and hypernatremia due to reduced renal function and comorbid conditions. Adjust based on cardiac status and renal function.
Consider lower initial doses due to decreased clearance. Use ideal body weight. Start at lower maintenance infusion rate (e.g., 0.3 mg/kg/h) and titrate based on serum levels and clinical response. Monitor for toxicity.
None.
None
Risk of fluid overload in patients with congestive heart failure, renal insufficiency, or hepatic cirrhosis.,Monitor serum glucose, electrolytes, and fluid balance; dextrose can cause hyperglycemia, especially in diabetic patients.,Do not administer simultaneously with blood through same tubing due to risk of RBC aggregation/hemolysis.,Intraosseous administration may cause compartment syndrome.,Use with caution in patients with preexisting electrolyte abnormalities or those receiving corticosteroids.
Narrow therapeutic index; serum theophylline levels must be monitored to avoid toxicity. Risk of seizures, cardiac arrhythmias, and death, especially at high serum concentrations. Caution in patients with hepatic impairment, congestive heart failure, cor pulmonale, fever, and in the elderly. Drug interactions with cimetidine, fluoroquinolones, macrolides, oral contraceptives, and other CYP1A2 inhibitors can increase toxicity.
Hyperglycemia with marked glycosuria or hyperosmolar coma.,Hypersensitivity to corn or corn products.,Severe electrolyte imbalances (e.g., hypernatremia) unless corrected.,Patients with anuria not related to hypovolemia.
Absolute: Hypersensitivity to theophylline, ethylenediamine, or any component; use in patients with active seizure disorder (unless receiving appropriate anticonvulsant therapy); use in patients with a history of ventricular arrhythmias (except under close supervision). Relative: Peptic ulcer disease, hyperthyroidism, hypertension, and renal impairment.
Avoid high-sodium foods as this solution already contains sodium chloride. Diabetic patients should monitor carbohydrate intake, as dextrose provides 5 g/100 m L. No direct food interactions, but overall sodium and glucose intake should be considered.
Avoid large amounts of caffeine-containing foods and beverages (coffee, tea, cola, chocolate) as they can potentiate theophylline effects and increase risk of toxicity. A high-protein diet may increase theophylline clearance; maintain consistent dietary habits.
Dextrose 5% in Sodium Chloride 0.9% is a crystalloid solution not associated with teratogenicity. No fetal risk has been identified in any trimester when used appropriately for fluid and electrolyte replacement. Maternal hyperglycemia or electrolyte disturbances may indirectly affect the fetus if improperly administered, but the solution itself is not teratogenic.
Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity but some developmental delays at high doses. Second and third trimesters: Use only if benefit outweighs risk; may cause fetal tachycardia or irritability due to adenosine receptor blockade. Avoid near term due to potential neonatal irritability.
Both dextrose and sodium chloride are normal constituents of breast milk. Administration of this solution does not pose a risk to the nursing infant. The M/P ratio is not applicable as these substances are endogenous and not actively concentrated in milk.
Not recommended unless essential. Aminophylline is excreted into breast milk; M/P ratio approximately 0.6–0.8. Monitor infant for irritability or insomnia. Consider alternative therapies if breastfeeding.
Pregnancy-related plasma volume expansion and increased glomerular filtration rate may require adjustments in infusion rate to avoid fluid overload or electrolyte imbalance. Dose should be individualized based on maternal fluid status, electrolyte levels, and renal function. No standard dose adjustment is necessary but careful titration is recommended.
Pregnancy may decrease protein binding and increase clearance of theophylline; monitor serum levels closely. Dose may need to be increased by 10–30% to maintain therapeutic levels. Postpartum, doses may need reduction.
Contains 5 g dextrose and 0.9 g sodium chloride per 100 m L; provides 170 kcal/L and 154 m Eq/L each of Na+ and Cl-. Monitor serum glucose in diabetic patients; avoid in hyperglycemia. Use with caution in heart failure, renal impairment, and hypertension due to sodium load. Incompatible with certain drugs (e.g., amphotericin B, erythromycin).
Aminophylline is a bronchodilator used primarily for asthma and COPD exacerbations. Monitor serum theophylline levels closely due to narrow therapeutic index (10-20 mcg/m L). Administer IV infusion over 30 minutes to avoid hypotension. Caution in patients with cardiac arrhythmias, hyperthyroidism, or seizure disorders. Drug interactions include cimetidine, fluoroquinolones, and macrolides which increase theophylline levels.
This solution provides sugar and salt to replace fluids and energy.,Tell your doctor if you have diabetes, high blood pressure, or heart or kidney problems.,You may experience swelling due to the salt content; report shortness of breath or leg swelling.,Do not consume additional salty foods unless advised by your doctor.,Your blood sugar and electrolytes will be monitored during treatment.
Take this medication exactly as prescribed; do not stop or change dose without consulting your doctor.,Avoid excessive caffeine intake (coffee, tea, chocolate, cola) as it may increase side effects like jitteriness and palpitations.,Report any symptoms of toxicity such as nausea, vomiting, insomnia, rapid heart rate, or seizures immediately.,Inform your healthcare provider of all other medications, especially antibiotics, heart medications, or seizure drugs.,Do not chew or crush the solution; it is for intravenous use only under medical supervision.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, answered by our medical review team.
DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Dextrose is a monosaccharide that provides a source of calories and fluid for intravenous administration. It increases blood glucose levels and may cause diuresis via osmotic effects. Sodium chloride provides electrolyte replacement to maintain or restore intravascular volume and extracellular fluid balance.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine. Theophylline acts as a non-selective phosphodiesterase inhibitor, increasing intracellular cyclic AMP levels, leading to bronchodilation. It also blocks adenosine receptors, stimulates catecholamine release, and enhances diaphragmatic contractility. The ethylenediamine component increases solubility.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: Intravenous infusion; typical adult dose is 100-200 m L/hour of D5 0.9% Na Cl, adjusted based on fluid and electrolyte status, glucose monitoring, and clinical indication.. The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is: Loading dose: 5-6 mg/kg IV over 20-30 minutes (if not on theophylline). Maintenance: 0.5-0.7 mg/kg/h IV continuous infusion.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Dextrose 5% in Sodium Chloride 0.9% is a crystalloid solution not associated with teratogenicity. No fetal risk has been identified in any trimester when used appropriately for flu. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is classified as Category A/B. Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity but some developmental delays at high doses. Second and third trimesters: Use only . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.